WIZP News and Press, Wize Pharma Inc From 12/30/20

Wize Pharma (WIZP) and Sydney-based digital infrastructure provider Cosmos Capital, entered into a bid implementation agreement, wherein the former has agreed to make an off-market takeover offer to acquire all of the outstanding shares of Cosmo.Post the transaction closure in 1Q21,...

Wize Pharma and Cosmos Capital enter into Bid Implementation Agreement - Cosmos Capital, a digital infrastructure provider, to become publicly traded through a business combination with Wize - The combined company is expected to have approximately US$5 million in cash and ca...

Wize Pharma ([[WIZP]] +33.3%) has reported topline results from its Phase IV exploratory study in Israel of its in-license eye drop formula, LO2A, for the symptomatic treatment of dry eye syndrome ((DES)) in patients with Sjögren's syndrome, a disorder in which the body's immune system a...

Wize Pharma Announces Positive Topline Results in Phase IV Study of LO2A for the Treatment of Dry Eye Syndrome in Patients with Sjögren's Syndrome - LO2A successfully demonstrated non-inferiority vs comparator on all efficacy endpoints treating dry eye signs and symptoms in...

HOD HASHARON, Israel , May 27, 2020 /PRNewswire/ -- Wize Pharma , Inc. (OTCQB: WIZP), a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, today announced that Bonus BioGroup (TASE: BONS.TA), a company in which Wize owns an 8.9% equity stake, will ...

HOD HASHARON, Israel , May 18, 2020 /PRNewswire/ --  Wize Pharma , Inc. (OTCQB: WIZP), a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, today announced that on May 13, 2020 , Bonus BioGroup (TASE: BONS.TA), a company in which Wize owns a...

HOD HASHARON, Israel , May 7, 2020 /PRNewswire/ -- Wize Pharma , Inc. (OTCQB: WIZP), a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, today announced it has completed treating patients in its Phase IV clinical trial of its prescription eye drop...

HOD HASHARON, Israel , April 21, 2020 /PRNewswire/ --  Wize Pharma , Inc. (OTCQB: WIZP), a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, today announced that Bonus BioGroup (TASE: BONS.TA), a company in which Wize owns 8.9% of its equity s...

HOD HASHARON, Israel , Feb. 20, 2020 /PRNewswire/ --  Wize Pharma , Inc. (OTCQB: WIZP), a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, today announced it has completed its previously announced strategic transaction with Bonus BioGroup Ltd...

Wize Pharma ( OTCQB:WIZP ) has completed enrollment in a Phase 4 clinical trial evaluating eye drop LO2A, branded as EyeCon in Israel, for the symptomatic treatment of dry eye syndrome (DES) in patients with an autoimmune disorder called Sjögren's syndrome (the immune system attacks g...